Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Praxis Precision Medicines (PRAX) Net Income towards Common Stockholders: 2022-2025

Historic Net Income towards Common Stockholders for Praxis Precision Medicines (PRAX) over the last 4 years, with Sep 2025 value amounting to -$78.4 million.

  • Praxis Precision Medicines' Net Income towards Common Stockholders fell 37.87% to -$78.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$293.1 million, marking a year-over-year decrease of 78.71%. This contributed to the annual value of -$200.2 million for FY2024, which is 58.39% down from last year.
  • Praxis Precision Medicines' Net Income towards Common Stockholders amounted to -$78.4 million in Q3 2025, which was down 3.01% from -$76.1 million recorded in Q2 2025.
  • Over the past 5 years, Praxis Precision Medicines' Net Income towards Common Stockholders peaked at -$25.5 million during Q3 2023, and registered a low of -$78.4 million during Q3 2025.
  • For the 3-year period, Praxis Precision Medicines' Net Income towards Common Stockholders averaged around -$50.5 million, with its median value being -$41.9 million (2024).
  • Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first soared by 44.67% in 2023, then crashed by 130.01% in 2024.
  • Praxis Precision Medicines' Net Income towards Common Stockholders (Quarterly) stood at -$41.5 million in 2022, then surged by 32.92% to -$27.8 million in 2023, then crashed by 130.01% to -$64.0 million in 2024, then plummeted by 37.87% to -$78.4 million in 2025.
  • Its Net Income towards Common Stockholders stands at -$78.4 million for Q3 2025, versus -$76.1 million for Q2 2025 and -$74.7 million for Q1 2025.